跳至主要内容
临床试验/NCT01695733
NCT01695733终止1 期

Influenza Vaccination Response in Patients With Non-Hematological Malignancies

Washington University School of Medicine2 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2011年9月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
21
试验地点
2
主要终点
Optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule.

研究概览

简要总结

This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different times relative to chemotherapy may affect how well it works to help the body build an immune response and prevent influenza in these patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have biopsy-confirmed non-hematological malignancy
  • Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic setting), excluding immunotherapy
  • Patients must be of age >=18 years.
  • Patients must have an absolute lymphocyte count >= 1,000/mcL immediately prior to influenza vaccination
  • Ability of the patient (or legally authorized representative if applicable) to understand and the willingness to sign a written informed consent document

排除标准

  • Patients who have already received the influenza vaccine during the season in which they are considered for eligibility will be excluded
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the influenza vaccine or egg allergies
  • Previous history of Guillian-Barre syndrome within the previous 6 weeks to influenza vaccination
  • Patients must not be receiving chronic steroid therapy, defined as >= 14 days, unless used as part of a chemotherapy regimen
  • Patients must not be on any other agents that can suppress the immune system
  • Planned concurrent therapy with radiation
  • Uncontrolled illness at time of enrollment or influenza vaccination including, but not limited to, ongoing or active febrile illness
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Known immunosuppression eg. history of organ transplantation or known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because they may not be able to mount an appropriate immune response
  • History of influenza-like illness, defined as a temperature > 37.8 degree C with cough or sore throat starting October 1, 2011 throughout the duration of the study
  • Patient may not be scheduled to receive chemotherapy on a weekly basis.

结局指标

主要结局

Optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule.

时间窗: 4 weeks from the influenza vaccine

We will assess co-primary endpoints of serologic response to the H3N2 and H1N1 strains in the 2011-2012 and 2012-2013 seasonal influenza vaccine.

次要结局

  • Report the presence of post-vaccination adverse events(4 weeks from the influenza vaccine)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验